Sun Pharmaceutical (SUNPHARMA) — Financial Results

1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Sun Pharmaceutical reported Q2 FY2025-26 consolidated revenue of ₹144,783.1 million with net profit of ₹31,179.5 million, reflecting 8.6% YoY sales growth and 2.6% YoY profit growth. EBITDA margin expanded to 31.3% with 14.9% YoY growth. The Board approved an amendment to the Memorandum of Association enabling captive renewable energy plants with grid-sale capabilities, aligned with ESG commitments. Exceptional charges of ₹2,876.4 million included SCD-044 drug discontinuation impairment and a US litigation settlement with Incyte granting deuruxolitinib rights.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

Sun Pharmaceutical held an earnings call on November 5, 2025, for FY26 Q2 results. The audio recording has been made available to investors on the company's website as per SEBI listing regulations. No financial metrics or material updates were disclosed in this announcement filing.

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this financial results affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 5 November 2025?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 5 November 2025

VEDL Vedanta Limited Financial Results DELHIVERY Delhivery Limited Financial Results DELHIVERY Delhivery Limited Financial Results DELHIVERY Delhivery Limited Announcement DELHIVERY Delhivery Limited Announcement DELHIVERY Delhivery Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.